Multivariate analyses for DFS, duration of CR, and overall survival
. | P . | ||
---|---|---|---|
DFS . | CR duration . | Overall survival . | |
Age, continuous variable | .16 | .35 | .10 |
WBC index, 3-group classification | .003 | .002 | .04 |
Hazard ratio (95% CI) | 1.9 (1.3-3.0) | 2.2 (1.3-3.7) | 1.6 (1.0-2.6) |
AA-AN, 2-group classification | .50 | .75 | .38 |
Six prospective studies3-150 | .48 | .99 | .55 |
Postremission therapy, ALLO/CHEMO classification | .89 | .15 | .60 |
. | P . | ||
---|---|---|---|
DFS . | CR duration . | Overall survival . | |
Age, continuous variable | .16 | .35 | .10 |
WBC index, 3-group classification | .003 | .002 | .04 |
Hazard ratio (95% CI) | 1.9 (1.3-3.0) | 2.2 (1.3-3.7) | 1.6 (1.0-2.6) |
AA-AN, 2-group classification | .50 | .75 | .38 |
Six prospective studies3-150 | .48 | .99 | .55 |
Postremission therapy, ALLO/CHEMO classification | .89 | .15 | .60 |
LAME-91, ALFA-9000, BGMT-87, BGMT-91, GOELAM-01, or GOELAM-02.